Health Predictions
21 sourced future predictions currently published in the Health category. Every prediction rests on a source, a criterion and a probability.
- The First In Vivo CRISPR-Cas9 Gene Editing Therapy, Lonvoguran Ziclumeran (Lonvo-z), Is Expected To Receive US FDA Approval In 2027 For Hereditary Angioedema. 2027
- AI-driven Drug Discovery Platforms Are Expected To Bring Their First Commercial Products To Market. 2027
- Gene Therapies Are Expected To Gain Widespread Approval For Rare Diseases And Enter Clinical Use. 2027
- Personalized MRNA Cancer Vaccines Are Expected To Show Promising Phase 3 Trial Results. 2027
- Moderna And Merck's Personalized MRNA Neoantigen Cancer Vaccine Intismeran Autogene (V940/mRNA-4157) Is Expected To Receive Its First Regulatory Approval In 2028 As Adjuvant Treatment For High-risk Melanoma. 2028
- AI-assisted Diagnostic Systems Are Expected To Reach Clinician-level Accuracy In Radiology And Pathology. 2028
- Genomics-based Personalized Medicine Is Expected To Become Standard Of Care In Oncology. 2028
- 3D Bioprinters Are Expected To Enter Clinical Use For Organ Transplantation. 2028
- By The End Of 2028, AI-powered Virtual Patient Systems İn Healthcare Simulation Centers Will Become A Standard Component Of Medical Education İn Turkey, With At Least 10 Medical Faculties İntegrating Them İnto Their Curricula. 2028
- The Personalized MRNA Cancer Vaccine From Moderna And Merck (Intismeran Combined With Keytruda) Will Receive Its First Approval From A Major Regulator (FDA Or EMA). 2029
- AI Diagnostic Systems Are Expected To Surpass Clinician-level Accuracy Across All Medical Imaging. 2029
- Bioprinters Are Expected To Be Able To Produce Fully Functional Organs. 2029
- Gene Therapies Are Expected To Start Being Used In Common Diseases Such As Cancer And Heart Disease. 2029
- A Genetically Edited Pig Kidney (Xenotransplant) Is Expected To Receive Its First Regulatory Approval By 2030 For End-stage Kidney Disease. 2030
- AI Diagnostic Systems Are Expected To Surpass Clinician-level Accuracy Across All Medical Fields. 2030
- Bioprinters Are Likely To Produce Fully Functional Organs And Eliminate Transplant Waitlists. 2030
- Gene Therapies Are Likely To Reach A Level Where They Can Treat All Genetic Diseases. 2030
- The First Gene Therapy Developed With Base-editing Technology Will Receive Regulatory Approval For Sickle Cell Disease Or Beta Thalassemia. 2032
- Continuous Glucose/cholesterol Monitoring With Biosensors Will Become Widespread. 2033
- Widespread Adoption Of AI-assisted Mental Health Therapies 2033
- AI-assisted Diagnostic Systems Reach Physician-level Performance Across All Medical Imaging 2035